Supply chain transparency is also emphasised as an essential factor in achieving sustainability goals.
The industry is heavily reliant on complex global supply chains, making traceability a persistent challenge.
The roadmap advocates for responsible sourcing of raw materials, increased supplier accountability and the adoption of alternative materials with lower environmental impacts.
Reducing solid waste
The report also stresses the importance of reducing solid waste across the value chain.
Pharmaceutical packaging, expired medications and production waste contribute to significant environmental harm.
Companies are encouraged to invest in circular economy initiatives, such as biodegradable packaging and take-back programmes for unused medicines.
What are the industry’s next steps?
One of the roadmap’s next steps is to establish clear nature-related metrics for tracking and reporting progress.
These standardised indicators will help businesses navigate evolving regulatory requirements while providing transparency to stakeholders.
“Nature loss and climate change present big challenges for the pharmaceutical sector,” says Will Evison, Director of Climate, Environment & Nature Strategy at PwC.
“Addressing these twin crises proactively can improve health outcomes and drive value creation.”